Not FDA-approved1,4Evidence: Smaller human trialsHormones

Hexarelin1

Also called Examorelin1

Key takeaway

Hexarelin is a synthetic six-amino-acid peptide that FDA’s substance registry lists under the international name examorelin.1 Small studies in healthy volunteers found that it raises growth hormone and also stress and lactation hormones such as cortisol and prolactin, and that it reduced deep sleep in one study of seven people.2,3 No FDA approval is reported in the sources reviewed here. Hexarelin does not appear on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.1,4,6

Hexarelin at a glance

What it isA synthetic hexapeptide amide containing 2-methyl-D-tryptophan, recorded as examorelin, hexarelin and EP-23905 in FDA’s substance registry.1
FDA statusNo FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page, current as of April 22, 2026, does not list hexarelin.1,4
Human evidenceSmall, short hormone studies in healthy volunteers, including a placebo-controlled study of seven people and a randomized study of six men.2,3
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is hexarelin?

Hexarelin is a synthetic peptide of six amino acids, His-(2-methyl)D-Trp-Ala-Trp-D-Phe-Lys-NH2. FDA’s substance registry records it as examorelin, its international name, and as hexarelin, EP-23905 and MF-6003.1

How is hexarelin thought to work?

Study authors describe hexarelin as a synthetic growth hormone secretagogue, a compound that acts at the same receptor as the natural hormone ghrelin to prompt the pituitary to release growth hormone.2

In a separate test within the same study, hexarelin also raised ACTH, cortisol and prolactin, showing that its effects are not limited to growth hormone.3

What do human studies show?

In a 2004 placebo-controlled study of seven healthy young volunteers, hexarelin reduced the deepest stage of sleep and raised growth hormone, prolactin, ACTH and cortisol during the night.2

In a 2002 study of six healthy young men, repeated hexarelin over one day raised 24-hour growth hormone release without changing IGF-I, prolactin, ACTH or cortisol, and it blunted the growth hormone response to a later test.3

These studies lasted a day or two and measured hormones; none of the sources reviewed here tests whether hexarelin treats any condition.2,3

What the evidence base contains

  • Controlled human trial A placebo-controlled study in seven healthy young volunteers that measured sleep and night-time hormone levels after hexarelin (2004).2
  • Small, short, or incompletely reported human study A one-day study in six healthy young men measuring 24-hour hormone release after repeated hexarelin, without a placebo group (2002).3

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is hexarelin FDA-approved?

None of the sources reviewed here reports an approval of hexarelin by FDA.1,4

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list hexarelin, either in category 2 or among withdrawn nominations.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Hexarelin is not among them.5,6

Timeline

  1. A one-day study of repeated hexarelin in six healthy men is published.3
  2. A placebo-controlled study of hexarelin and sleep in seven healthy volunteers is published.2
  3. FDA’s compounding safety-risk page is last updated; it does not list hexarelin.4

What is still unknown?

Whether it is effective or safe for any condition, or with longer use: the studies cited here were small and lasted a day or two.2,3

Whether its effect on deep sleep, seen in seven volunteers, would appear in larger groups.2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Hexarelin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Hexarelin are a bounded selection, not every registration or paper about Hexarelin. For the years before Hexarelin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Hexarelin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Hexarelin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported. Human data come from small, short hormone studies in healthy volunteers. Hexarelin is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Hexarelin?

No FDA approval reported. Human data come from small, short hormone studies in healthy volunteers. Hexarelin is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
1
Source years
7
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 16, 2026

    Hepatic extraction of hexarelin, a new peptidic GH secretagogue, in the isolated perfused rat liver.↗Source date October 19, 2026
  2. Literature metadata · added November 16, 2026

    Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa.↗Source date October 12, 2026
  3. Literature metadata · added November 16, 2026

    Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.↗Source date March 9, 2022

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Hexarelin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

24Selected dated records
30Connected citations
7Populated source years2012–2026
1/4Record lanes present

Registered human studies

Trial composition

0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

PubMed bibliography

Publication composition

24 of 24 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 23Research Support, Non-U.S. Gov't 12Clinical Trial 6Comparative Study 6Evaluation Study 2Randomized Controlled Trial 2Controlled Clinical Trial 1Letter 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
24

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 24 dated records

Research hub

Explore the Hexarelin evidence record

Open all 24 records →
24Dated records
1Evidence type
24Cited public sources
7Source years

Change ledger

Recently changed for Hexarelin

Open all 24 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

Hexarelin as a test of pituitary reserve in patients with pituitary disease.

PubMed lists PMID 10469018 in Clinical endocrinology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-09 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
August 13, 2019
Evidence lane
Literature metadata
Record added

Hexarelin, a growth hormone - releasing peptide, counteracts bone loss in gonadectomized male rats.

PubMed lists PMID 10512687 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 15, 2012
Evidence lane
Literature metadata
Record added

Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats.

PubMed lists PMID 10611139 in Drug metabolism and disposition: the biological fate of chemicals as Journal Article, with publication-date metadata of 2000-01 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 15, 2012
Evidence lane
Literature metadata

Official-source collections

Source records for Hexarelin

Open the full research atlas →

Evidence types

Coverage by source year

Selected records span November 15, 2012 to October 19, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,4
  • U.S. Department of Health and Human Services5
Dated updates connected to this profile · 24

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Hepatic extraction of hexarelin, a new peptidic GH secretagogue, in the isolated perfused rat liver.↗

    PubMed lists PMID 9279881 in Pharmaceutical research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-08 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa.↗

    PubMed lists PMID 9258804 in Journal of endocrinological investigation as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1997-05 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.↗

    PubMed lists PMID 11238504 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2001-03 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.↗

    PubMed lists PMID 9801989 in Journal of endocrinological investigation as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-09 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Hexarelin Signaling to PPARgamma in Metabolic Diseases.↗

    PubMed lists PMID 18288286 in PPAR research as Journal Article, with publication-date metadata of 2008 (year precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Hexarelin: a multi-receptor peptide.↗

    PubMed lists PMID 18787392 in Journal of endocrinological investigation as Letter, with publication-date metadata of 2008-07 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion.↗

    PubMed lists PMID 32403043 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2020-05-08 (day precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy.↗

    PubMed lists PMID 11959048 in European journal of heart failure as Comparative Study, Evaluation Study, Journal Article, with publication-date metadata of 2002-03 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Reproductive performance and fertility in male and female adult mice chronically treated with hexarelin.↗

    PubMed lists PMID 22401277 in Reproduction, fertility, and development as Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012 (year precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Does desensitization to hexarelin occur?↗

    PubMed lists PMID 10990150 in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society as Clinical Trial, Journal Article, with publication-date metadata of 1998-04 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Permeability of the peptidic GH secretagogues hexarelin and EP 51389, across rat jejunum.↗

    PubMed lists PMID 11445244 in Peptides as Journal Article, with publication-date metadata of 2001-07 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Hexarelin as a test of pituitary reserve in patients with pituitary disease.↗

    PubMed lists PMID 10469018 in Clinical endocrinology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-09 (month precision). PeptideScanner associated the retained record with the identity slug hexarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Examorelin (hexarelin) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  2. 2
    Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers (2004) · PMID 15177700 ↗

    Psychoneuroendocrinology · Official source · Source checked November 15, 2026

  3. 3
    Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans (2002) · PMID 11888836 ↗

    European Journal of Endocrinology · Official source · Source checked November 15, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026